Close

Sun Pharma gets FDA acceptance for Cranbury manufacturing palnt.

Related stories

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Elevating Biopharmaceutical Projects With The Right CDMO

In the biopharma industry, selecting the right contract development...

Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

Biovian, a leading contract development and manufacturing organization (CDMO)...

New PAT – Based Strategy Stops Membrane Fouling In SP – TFF

A recent article published in the Journal of Membrane...

Sun Pharmaceutical has received the US Food and Drug Administration (FDA) acceptance for its manufacturing plant at Cranbury in New Jersey, US.

Earlier, the company has received a warning letter from the agency on 25 August 2010 for violating good manufacturing practice regulations. The issuance of the letter follows FDA inspection of the site.

Caraco, now wholly owned by Sun Pharma, continues to work with consultants to resolve the issues raised by the FDA at its Detroit plant.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories